There has been an increase in the sales of injectable anti-diabetic drugs containing the active ingredient semaglutide in Russia. According to reports, the sales volume of goods at the end of the first quarter exceeded the figure for the whole of 2023 TASS citing data from pharmaceutical company Geropharm.
Petr Rodionov, president of Geropharm, noted that in many ways this jump in sales was due to the launch of the new drug Semavik, which is an analogue of the Danish Ozempic. According to him, in the January-March period, Samavik accounted for 69% of sales.
“What influenced the increase in demand was the clarity of distribution channels. Last year Ozempic was purchased second hand. Prices were 20-40 thousand rubles per package. Rodionov noted that currently the cost of the drug in any pharmacy is 5-6 thousand rubles.
Before that in Russia was recorded A sharp increase in demand for Botox and its analogues. Sales of drugs from the botulinum toxin group increased by 139% in terms of units and 123% in monetary terms in the first quarter.
Previously reportedIt was announced that the Japanese pharmaceutical company Kobayashi Pharmaceutical lost 24 million dollars due to the food additives scandal.
What are you thinking?
Source: Gazeta
Ben Stock is a business analyst and writer for “Social Bites”. He offers insightful articles on the latest business news and developments, providing readers with a comprehensive understanding of the business world.